Holen Sie sich die Stockscreener-App
78.19
0.80%
-0.905
Grail Inc Aktie (GRAL) Neueste Nachrichten
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 - finance.yahoo.com
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test - finance.yahoo.com
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Have Insiders Sold GRAIL Shares Recently? - simplywall.st
GRAIL grants 55,867 RSUs to 59 new employees as hiring incentive under Nasdaq rules. - Pluang
GRAIL (GRAL) Institutional Ownership 2026 $GRAL - MarketBeat
Grail CFO Aaron Freidin sells $671,579 in company stock By Investing.com - Investing.com South Africa
Grail CFO Aaron Freidin sells $671,579 in company stock - Investing.com
Grail CEO Joshua Ofman sells $425,098 in company stock - Investing.com
GRAIL CFO sells 7,900 shares at $85.01 avg - Stock Titan
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference - TradingView
GRAIL (NASDAQ: GRAL) insider Joshua Ofman plans to sell 10,000 shares - Stock Titan
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Biotech Frenzy Sends GRAIL Soaring Ahead of FDA Showdown - TipRanks
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ: GRAL) over potential Wrongdoing - openPR.com
GRAIL (GRAL) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Current Update; Post-Report: The Market Price Advances 6.19% in Latest TradingGross Profit Margin - dars.gov.et
Grail Stock Rockets Back As Traders Buy The Dip - TipRanks
GRAIL (GRAL), What Is Behind The Fresh Attention On The Stock? - simplywall.st
Why Silver Grail Resources Ltd stock is skyrocketing today - Wealth Awesome
Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
How (GRAL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
GRAL Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Season Review - Vinanet
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - TradingKey
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL Q2 2026 Earnings: EPS Beats Estimates by 5.37% Amid Muted Stock ReactionEarnings Acceleration Picks - Vinanet
GRAIL Inc. (GRAL) Edges Lower 0.84% as Shares Hold Above $64.94 SupportValue Area Low - Vinanet
GRAIL2026 Funding Rounds & List of Investors - Tracxn
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
GRAIL INC : PIPER SANDLER RAISES TARGET PRICE TO $74 FROM $56 - webull.com
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - marketbeat.com
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - Benzinga
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial - Endpoints News
FDA panel to review GRAIL’s cancer detection test on Sept. 23 - Investing.com
GRAIL Insiders Sold US$29m Of Shares Suggesting Hesitancy - Moomoo
GRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking Alpha
GRAIL Says FDA Advisory Committee To Review GRAIL Galleri PMA Application On September 23 - TradingView
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PR Newswire
Analysts Offer Insights on NA Companies: GRAIL Inc (GRAL) and SanDisk Corp (SNDK) - The Globe and Mail
State Street Corporation (NASDAQ: GRAL) reports 5.6% beneficial stake in GRAIL - Stock Titan
GRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs - insights.citeline.com
Dimensional Fund Advisors LP Purchases 191,857 Shares of GRAIL, Inc. $GRAL - marketbeat.com
PRIMECAP Management (GRAL) discloses 21.8M-share, 5.08% stake in GRAIL - Stock Titan
GRAIL, Inc. 2026: Revenue $44.69M, EPS ($2.56) — 10-Q Summary - TradingView
[10-Q] GRAIL, Inc. Quarterly Earnings Report - Stock Titan
GRAIL (NASDAQ:GRAL) Shares Down 12.2%What's Next? - MarketBeat
GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
GRAIL, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
2.22%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):